Health Economic Evaluation of the Theranova 400 Dialyzer Among Hemodialysis Patients in the United States: Results from a Randomized-Controlled Trial
- "All-cause hospitalization rate was 43% lower with Theranova compared to Elisio (p=0.069). Average annual cost of hospitalization was $3,925 lower with Theranova
Annual cost of ESAs and iron were similar, although cost of ESAs was $400 lower in the Theranova group"